Related Experiment Videos
Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1
L Shapiro1, G B Pott, A H Ralston
1Department of Medicine, Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA. leland.shapiro@uchsc.edu
Summary
Alpha-1-antitrypsin (AAT), a natural protease inhibitor, significantly reduces human immunodeficiency virus type 1 (HIV-1) production and replication. This suggests AAT as a potential in vivo HIV-1 inhibitor, offering new therapeutic strategies.
Area of Science:
- Virology
- Immunology
- Biochemistry
Background:
- Endogenous suppressors of human immunodeficiency virus type 1 (HIV-1) production are suggested by observations.
- Serine protease inhibitors may play a role in suppressing HIV-1.
- Alpha-1-antitrypsin (AAT) is the most abundant circulating serine protease inhibitor.
Purpose of the Study:
- To investigate the role of Alpha-1-antitrypsin (AAT) as a potential endogenous inhibitor of HIV-1.
- To explore the mechanisms by which AAT affects HIV-1 production and replication.
- To assess the potential of AAT as a therapeutic strategy for HIV-1 related diseases.
Main Methods:
- Inhibition of HIV-1 production in chronically infected U1 monocytic cells using physiological AAT concentrations.
- Assessment of AAT's effect on virus replication in freshly infected peripheral blood mononuclear cells.
- Evaluation of AAT's impact on HIV-1 infection in permissive HeLa cells and NF-kappaB activation.
- Comparison of HIV-1 replication in blood from healthy volunteers versus individuals with hereditary AAT deficiency.
- Utilizing CE-2072, a synthetic serine protease inhibitor, for comparative analysis.
Main Results:
- Physiological AAT concentrations inhibited HIV-1 production in U1 cells and reduced virus replication in peripheral blood mononuclear cells.
- AAT blocked HIV-1 infection in HeLa cells and suppressed NF-kappaB activation in U1 cells.
- HIV-1 did not replicate in blood from healthy volunteers, but showed marked replication in individuals with hereditary AAT deficiency.
- CE-2072, a synthetic inhibitor, yielded similar results to AAT.
- Two mechanisms of AAT-induced HIV-1 inhibition were identified: reduced infectivity and blocked production.
Conclusions:
- Alpha-1-antitrypsin (AAT) is identified as a candidate circulating HIV-1 inhibitor in vivo.
- AAT exhibits dual mechanisms of action against HIV-1: reducing infectivity and blocking viral production.
- These findings suggest a novel host-pathogen interaction and propose AAT as a potential alternative therapeutic strategy for HIV-1 related disease.